Format

Send to

Choose Destination
See comment in PubMed Commons below
Stem Cells. 2011 Jun;29(6):913-9. doi: 10.1002/stem.643.

Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors.

Author information

1
Department of Anesthesiology, University of California San Francisco, California 94143, USA. leejw@anesthesia.ucsf

Abstract

Morbidity and mortality have declined only modestly in patients with clinical acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), despite extensive research into the pathophysiology. Current treatment remains primarily supportive with lung-protective ventilation and a fluid conservative strategy. Pharmacologic therapies that reduce the severity of lung injury in preclinical models have not yet been translated to effective clinical treatment options. Consequently, further research in translational therapies is needed. Cell-based therapy with mesenchymal stem cells (MSCs) is one attractive new therapeutic approach. MSCs have the capacity to secrete multiple paracrine factors that can regulate endothelial and epithelial permeability, decrease inflammation, enhance tissue repair, and inhibit bacterial growth. This review will focus on recent studies, which support the potential therapeutic use of MSCs in ALI/ARDS, with an emphasis on the role of paracrine soluble factors.

PMID:
21506195
PMCID:
PMC3293251
DOI:
10.1002/stem.643
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Wiley Icon for PubMed Central
    Loading ...
    Support Center